

## [Simeprevir](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines](#) [6.4. Antiviral medicines](#) [6.4.4. Antihepatitis medicines](#) [6.4.4.2. Medicines for hepatitis C](#)  
[6.4.4.2.2. Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations](#)

ATC codes: [J05AP05](#)

Indication

Chronic hepatitis C ICD11 code: [1E91.1](#)

INN

Simeprevir

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Solid:** 150 mg

EML status history

First added in 2015 ([TRS 994](#))

Removed in 2019 ([TRS 1021](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Read more [about patents](#).

Wikipedia

[Simeprevir](#)

[DrugBank](#)

[Simeprevir](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee considered whether it was appropriate to delete non-pangenotypic treatments for hepatitis C, and recommended the deletion of simeprevir, whose place in therapy was now superseded by the pan-genotypic options. The Committee recommended that other non-pangenotypic treatments could be considered for deletion from the EML in the future.